CHU Hopital Sud

Amiens 80054

0 studies enrolling now · 2 studies all time

What they study most

Assess the Benefits From the AAISafeR/SafeR Algorithm of Symphony 2550 or REPLYTM DR in a Wide Range of Pacemaker Patients., Post- Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Primary Myelofibrosis

Studies at this site

• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib — Completed
• Evaluation of the SafeR Mode in Patients With a Dual Chamber Pacemaker Indication — Completed